As one of the latest gene therapy applications for alpha-1 antitrypsin (AAT) deficiency, Shen et al. (2018) employed two CRISPR-based approaches to reduce liver aggregates and increase AAT-M levels in in vivo transgenic mouse models (PiZ). The gene discussed is SERPINA1; the disease is alpha 1-antitrypsin deficiency.